- Home
- POR vs ACLX Comparison
POR vs ACLX Comparison
Compare POR & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POR
- ACLX
- Stock Information
- Founded
- POR 1889
- ACLX 2015
- Country
- POR United States
- ACLX United States
- Employees
- POR N/A
- ACLX N/A
- Industry
- POR Electric Utilities: Central
- ACLX Biotechnology: Pharmaceutical Preparations
- Sector
- POR Utilities
- ACLX Health Care
- Exchange
- POR Nasdaq
- ACLX Nasdaq
- Market Cap
- POR 4.9B
- ACLX 5.3B
- IPO Year
- POR N/A
- ACLX 2022
- Fundamental
- Price
- POR $44.62
- ACLX $82.04
- Analyst Decision
- POR Buy
- ACLX Strong Buy
- Analyst Count
- POR 9
- ACLX 15
- Target Price
- POR $49.13
- ACLX $104.46
- AVG Volume (30 Days)
- POR 869.8K
- ACLX 476.7K
- Earning Date
- POR 10-25-2024
- ACLX 11-07-2024
- Dividend Yield
- POR 4.49%
- ACLX N/A
- EPS Growth
- POR 51.49
- ACLX N/A
- EPS
- POR 3.35
- ACLX N/A
- Revenue
- POR $3,341,000,000.00
- ACLX $155,818,000.00
- Revenue This Year
- POR $9.10
- ACLX $12.58
- Revenue Next Year
- POR $5.71
- ACLX N/A
- P/E Ratio
- POR $13.28
- ACLX N/A
- Revenue Growth
- POR 15.81
- ACLX 230.33
- 52 Week Low
- POR $39.14
- ACLX $47.88
- 52 Week High
- POR $49.85
- ACLX $107.37
- Technical
- Relative Strength Index (RSI)
- POR 32.48
- ACLX 41.82
- Support Level
- POR $43.95
- ACLX $81.52
- Resistance Level
- POR $48.40
- ACLX $90.23
- Average True Range (ATR)
- POR 0.68
- ACLX 4.85
- MACD
- POR -0.23
- ACLX -0.60
- Stochastic Oscillator
- POR 20.41
- ACLX 9.66
About POR Portland General Electric Co
Portland General Electric is a regulated electric utility providing generation, transmission, and distribution services in a service territory that includes about half of all Oregon residents and two thirds of the state's business activity. The company owns (wholly or through joint ventures) 3.5 gigawatts of gas, coal, wind, and hydro generation.
About ACLX Arcellx Inc.
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.